These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 28201843)

  • 1. Regression of Liver Fibrosis.
    Campana L; Iredale JP
    Semin Liver Dis; 2017 Feb; 37(1):1-10. PubMed ID: 28201843
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhang GZ; Sun HC; Zheng LB; Guo JB; Zhang XL
    World J Gastroenterol; 2017 Dec; 23(46):8152-8168. PubMed ID: 29290652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and cellular mechanisms of liver fibrosis and its regression.
    Kisseleva T; Brenner D
    Nat Rev Gastroenterol Hepatol; 2021 Mar; 18(3):151-166. PubMed ID: 33128017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocytes and macrophages as cellular targets in liver fibrosis.
    Heymann F; Trautwein C; Tacke F
    Inflamm Allergy Drug Targets; 2009 Sep; 8(4):307-18. PubMed ID: 19534673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?
    Yi HS; Jeong WI
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():99-104. PubMed ID: 23855303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice.
    Ma PF; Gao CC; Yi J; Zhao JL; Liang SQ; Zhao Y; Ye YC; Bai J; Zheng QJ; Dou KF; Han H; Qin HY
    J Hepatol; 2017 Oct; 67(4):770-779. PubMed ID: 28596109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.
    Iredale JP; Pellicoro A; Fallowfield JA
    Dig Dis; 2017; 35(4):310-313. PubMed ID: 28467988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversibility of liver fibrosis.
    Ramachandran P; Iredale JP
    Ann Hepatol; 2009; 8(4):283-91. PubMed ID: 20009126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells.
    Knight V; Tchongue J; Lourensz D; Tipping P; Sievert W
    Hepatology; 2012 Mar; 55(3):879-87. PubMed ID: 22095855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy.
    Cai X; Wang J; Wang J; Zhou Q; Yang B; He Q; Weng Q
    Pharmacol Res; 2020 May; 155():104720. PubMed ID: 32092405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The roles of Kupffer cells in the development and regression of liver fibrosis].
    Wu JY; Liu GT
    Yao Xue Xue Bao; 2008 Sep; 43(9):884-9. PubMed ID: 19048777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.
    Tanwar S; Rhodes F; Srivastava A; Trembling PM; Rosenberg WM
    World J Gastroenterol; 2020 Jan; 26(2):109-133. PubMed ID: 31969775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C/EBP-α ameliorates CCl(4)-induced liver fibrosis in mice through promoting apoptosis of hepatic stellate cells with little apoptotic effect on hepatocytes in vitro and in vivo.
    Tao LL; Cheng YY; Ding D; Mei S; Xu JW; Yu J; Ou-Yang Q; Deng L; Chen Q; Li QQ; Xu ZD; Liu XP
    Apoptosis; 2012 May; 17(5):492-502. PubMed ID: 22307857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview.
    Pinheiro D; Dias I; Ribeiro Silva K; Stumbo AC; Thole A; Cortez E; de Carvalho L; Weiskirchen R; Carvalho S
    Cells; 2019 Oct; 8(11):. PubMed ID: 31671842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis.
    An P; Wei LL; Zhao S; Sverdlov DY; Vaid KA; Miyamoto M; Kuramitsu K; Lai M; Popov YV
    Nat Commun; 2020 May; 11(1):2362. PubMed ID: 32398673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-fibrogenic strategies and the regression of fibrosis.
    Kisseleva T; Brenner DA
    Best Pract Res Clin Gastroenterol; 2011 Apr; 25(2):305-17. PubMed ID: 21497747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.
    Thomas JA; Pope C; Wojtacha D; Robson AJ; Gordon-Walker TT; Hartland S; Ramachandran P; Van Deemter M; Hume DA; Iredale JP; Forbes SJ
    Hepatology; 2011 Jun; 53(6):2003-15. PubMed ID: 21433043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-fibrotic treatments for chronic liver diseases: The present and the future.
    Odagiri N; Matsubara T; Sato-Matsubara M; Fujii H; Enomoto M; Kawada N
    Clin Mol Hepatol; 2021 Jul; 27(3):413-424. PubMed ID: 33317250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice.
    Matsuda M; Tsurusaki S; Miyata N; Saijou E; Okochi H; Miyajima A; Tanaka M
    Hepatology; 2018 Jan; 67(1):296-312. PubMed ID: 28779552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of N-nitrosodimethylamine, methylation of macromolecules, and development of hepatic fibrosis in rodent models.
    George J; Tsuchishima M; Tsutsumi M
    J Mol Med (Berl); 2020 Sep; 98(9):1203-1213. PubMed ID: 32666246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.